cyclohex-1-en-4-yl fluoride | 2266-53-7

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: cyclohex-1-en-4-yl fluoride
• 英文别名: 4-fluorocyclohexene；4-Fluor-cyclohexen；4-Fluorocyclohexen
• CAS: 2266-53-7
• 化学式: C₆H₉F
• 分子量: 100.136
• InChiKey: SPOAMLFCRBFURV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  5-fluoronona-1,8-diene 在 [1,3-bis(2,4,6-trimethylphenyl)-2-imidazolidinylidene]dichloro-(3-phenyl-1H-inden-1-ylidene)(tricyclohexylphosphine)ruthenium(II) 作用下， 以 氘代甲苯 为溶剂， 生成 cyclohex-1-en-4-yl fluoride 、 5-fluorocyclohept-1-ene
  参考文献：
  名称：

  宝石-二氟亚甲基在闭环烯烃复分解反应中的加速影响。Thorpe-Ingold效应？

  摘要：

  相对于亚甲基（CH2）基团，二氟亚甲基（CF2）基团显着加快了1,8-壬二烯的闭环复分解反应，显示出与经典索普-英戈尔德取代基，二酯丙二酸酯和缩酮所观察到的相似的速率加速。

  DOI：

  10.1039/c3cc44312d

文献信息

• [EN] ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS FUSIONNÉS D'ACIDE CYCLOPENTANE-CARBOXYLIQUE À SUBSTITUTION ACYLAMINO, ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2009135590A1

  公开（公告）日：2009-11-12

  The present invention relates to compounds of the formula (I), wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

  本发明涉及具有式(I)的化合物，其中A，Y，Z，R3至R6，R20至R22和R50具有权利要求中指出的含义，它们是有价值的药物活性化合物。具体而言，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体可被溶血磷脂酸（LPA）激活，也被称为LPA1受体，并且可用于治疗例如动脉粥样硬化、心肌梗死和心力衰竭等疾病。本发明还涉及制备式(I)化合物的方法、它们的使用以及包含它们的药物组合物。
• PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS
  申请人：Dvorak A. Curt

  公开号：US20070032481A1

  公开（公告）日：2007-02-08

  Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases.

  某些含嘧啶的化合物是有效的血清素受体调节剂，可用于治疗血清素介导的疾病。
• [EN] BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE UTILES EN TANT QUE MODULATEURS DU RÉCEPTEUR TRP M8
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2010132247A1

  公开（公告）日：2010-11-18

  The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8 (transient receptor potential M8 channel). More particularly, the compounds of the present invention are useful in the treatment of inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold, anxiety and depression.

  本发明涉及苯并咪唑衍生物，含有它们的药物组合物以及它们在治疗由TRP M8（瞬时受体电位M8通道）调节的疾病和症状中的应用。更具体地说，本发明的化合物在治疗炎症性疼痛、炎症性过敏症、炎症性过敏性疾病、神经病性疼痛、神经性寒冷触痛、炎症性体感过敏症、炎症性内脏过敏症、受寒加重的心血管疾病、焦虑和抑郁方面具有用处。
• [EN] ACYLAMINO-SUBSTITUTED CYCLIC CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] DÉRIVÉS CYCLIQUES ACYLAMINO-SUBSTITUÉS DE L'ACIDE CARBOXYLIQUE ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI AVENTIS

  公开号：WO2011053948A1

  公开（公告）日：2011-05-05

  The present invention relates to compounds of the formula (I) wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.

  本发明涉及式(I)的化合物，其中A、Y、Z、R20至R22和R50具有索引中指示的含义，这些化合物是有价值的药用活性化合物。具体来说，它们是内皮分化基因受体2（Edg-2，EDG2）的抑制剂，该受体被溶血磷脂酸（LPA）激活，也被称为LPA1受体，对于治疗动脉粥样硬化、心肌梗死和心力衰竭等疾病是有用的。此外，本发明还涉及制备式(I)化合物的方法、它们的用途以及包含它们的药物组合物。
• Reaction of alkylhypochlorites and xenon difluoride with cyclohexene
  作者：Dale F. Shellhamer、Mark J. Horney、Andrew L. Toth、Victor L. Heasley

  DOI：10.1016/s0040-4039(00)60891-2

  日期：1992.11

  Reactions of alkylhypochlorites and xenon difluoride with cyclohexene give primarily 1-chloro-2-fluorocyclohexanes via formation of a complex between xenon difluoride and the alkylhypochlorite.

  次氯酸亚烷基酯和二氟化氙与环己烯的反应通过在二氟化氙和次氯酸烷基酯之间形成络合物，主要生成1-氯-2-氟环己烷。